Pharmaceuticals

The Intratumoral Cancer Therapies Market Is Witnessing Impact From Rising Prevalence Of Fungal Infections Driving Growth Due To Increased Need For Effective Antifungal Therapies

April 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, What Market Size Is The Intratumoral Cancer Therapies Market Expected To Reach Based On Its 2026 Value?

The intratumoral cancer therapies market size has demonstrated significant expansion in recent years. It is anticipated to increase from $156.96 billion in 2025 to $174.75 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.3%. The historical period’s growth can be attributed to several factors including limited treatment specificity, a substantial reliance on chemotherapy, infrequent adoption of immunotherapy, established conventional tumor injection methods, and inconsistencies in regional healthcare infrastructure.

The market for intratumoral cancer therapies is projected to experience swift expansion over the coming years. This market is set to reach $274.76 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.0%. Key factors driving this growth during the forecast period include the increasing adoption of precision medicine, the expanding application of immuno-oncology therapies, innovations in injection device technology, a surge in collaborations with biotechnology companies, and greater funding for cancer research. Significant trends anticipated in this period encompass targeted intratumoral drug delivery methods, combined therapy strategies, individualized cancer treatments, less invasive administration techniques, and improved modulation of the tumor microenvironment.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9979&type=smp

What Key Drivers Are Fueling The Growth Of The Intratumoral Cancer Therapies Market?

The growing occurrence of cancer is anticipated to drive the expansion of the intratumoral cancer therapies market in the future. Cancer refers to a collection of illnesses marked by the unregulated proliferation and dissemination of atypical cells within the body. These therapies, intratumoral cancer therapies, find application in both identifying and managing cancer, assisting in the prevention of off-target toxicities, dose-limiting toxicities, and unwanted consequences stemming from immune stimulation in individuals afflicted with cancer. As an illustration, in January 2023, the American Cancer Society, a U.S.-based nonprofit cancer advocacy organization, forecast around 1,958,310 new cancer diagnoses for 2023 in the United States, a figure that contrasts with roughly 1,918,160 new cases reported in 2022, signifying an increase of about 2.1%. Consequently, the rising occurrence of cancer is fueling the expansion of the intratumoral cancer therapies market.

How Are Segments Identified Within The Intratumoral Cancer Therapies Market Segment Framework?

The intratumoral cancer therapies market covered in this report is segmented –

1) By Technology: Monoclonal Antibodies, Vaccines, Checkpoint Inhibitors, Cell Therapies, Immunes System Modulator, Adoptive Cell Transfer, Cytokines

2) By Application: Lung Cancer, Breast Cancer, Melanoma, Prostate Cancer, Head And Neck Cancer, Other Applications

3) By End Users: Hospitals, Cancer Research Centers, Clinics

Subsegments:

1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies

2) By Vaccines: Peptide-Based Vaccines, Protein-Based Vaccines, DNA Vaccines

3) By Checkpoint Inhibitors: PD-1 Or PD-L1 Inhibitors, CTLA-4 Inhibitors

4) By Cell Therapies: CAR T-Cell Therapy, TCR Therapy

5) By Immune System Modulators: Immune Checkpoint Inhibitors, Toll-Like Receptor Agonists

6) By Adoptive Cell Transfer: Tumor-Infiltrating Lymphocytes (TILs), Peripheral Blood Lymphocytes (PBLs)

7) By Cytokines: Interleukins, Interferons, Tumor Necrosis Factor (TNF)

What Trends Are Shaping The Future Of The Intratumoral Cancer Therapies Market?

Leading firms in the intratumoral cancer therapies market are concentrating on creating novel solutions, including sophisticated oncolytic virus platforms, to address the increasing need for focused tumor elimination, improved immune responses, and advanced localized cancer treatments. These oncolytic virus therapies involve genetically modified viral structures that are engineered to specifically reproduce within cancer cells, leading to direct tumor breakdown and concurrently stimulating a body-wide anti-tumor immune response, thereby presenting a more precise and immune-boosting option compared to conventional chemotherapy and radiation. As an illustration, in November 2024, Replimune Group, Inc., a U.S.-based clinical-stage biotechnology company, disclosed that its primary experimental drug, RP1 (vusolimogene oderparepvec) — an engineered herpes simplex virus equipped with a fusogenic protein and GM-CSF — had been granted Breakthrough Therapy Designation by the FDA, with its Biologics License Application also submitted via the Accelerated Approval pathway. This particular technology facilitates the intratumoral administration of an oncolytic virus that directly eliminates tumor cells and enhances systemic immune reactions, marking a notable progression in cancer therapy.

Who Are The Companies Competing Within The Intratumoral Cancer Therapies Market?

Major companies operating in the intratumoral cancer therapies market are Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, Johnson & Johnson, Eli Lilly and Company, F. Hoffmann-la Roche, Takeda Pharmaceutical Company Ltd., GSK plc, Ziopharm Oncology Inc., Celldex Therapeutics Inc., Astellas Pharma Inc., Sirnaomics, Checkmate Pharmaceuticals Inc., Immunovative Therapies Ltd., Idera Pharmaceuticals Inc., Daiichi Sankyo, Philogen S.p.A., Apexigen Inc., Merck Group, OncoSec Medical Incorporated, DNAtrix, Istari Oncology Inc., Nanobiotix, Exicure Inc., Karyopharm Therapeutics Inc., Torigen Pharmaceuticals Inc.

Get The Full Intratumoral Cancer Therapies Market Report:

https://www.thebusinessresearchcompany.com/report/intratumoral-cancer-therapies-global-market-report

Which Region Leads The Intratumoral Cancer Therapies Market In Terms Of Market Share?

North America was the largest region in the intratumoral cancer therapies market in 2025. The regions covered in the intratumoral cancer therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Intratumoral Cancer Therapies Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/intratumoral-cancer-therapies-global-market-report

Browse Through More Reports Similar to the Global Intratumoral Cancer Therapies Market 2026, By The Business Research Company

Intratumoral Cancer Therapies Market Report 2026

https://www.thebusinessresearchcompany.com/report/intratumoral-cancer-therapies-global-market-report

Intestine Cancer Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/intestine-cancer-therapeutics-global-market-report

Appendiceal Cancer Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/appendiceal-cancer-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795